A Cal­i­for­nia in­fu­sion ther­a­py com­pa­ny is vol­un­tar­i­ly re­call­ing one lot of an amino acid in­jec­tion made by Pfiz­er spin­out com­pa­ny Hos­pi­ra af­ter re­ports of fibers, hair and oth­er par­ti­cles of for­eign ma­te­ri­als were found in the so­lu­tion.

ICU Med­ical re­called 2,112 units of Aminosyn II, 15%, af­ter it be­came aware of the is­sue while in­spect­ing sam­ples as part of a rou­tine process, the FDA said. The ad­min­is­tra­tion of a drug with par­tic­u­lates that do not be­long can cause side ef­fects rang­ing from in­flam­ma­tion at the point of in­jec­tion to blood clots. So far, ICU Med­ical hasn’t re­port­ed any side ef­fects or ill­ness­es stem­ming from the con­t­a­m­i­na­tion.

Aminosyn II is a food re­place­ment IV drip that is used in pa­tients who are un­able to con­sume food the typ­i­cal way. It can al­so be used to pre­serve pro­tein and re­duce the break­down of sug­ars, fat­ty acids and pro­teins in stress con­di­tions. Aminosyn II can al­so be used to pre­vent or re­verse ex­cret­ing more ni­tro­gen than is tak­en in when feed­ing tubes should not be used.

The lot has an ex­pi­ra­tion date of April 1, 2022, and was man­u­fac­tured by ICU Med­ical in No­vem­ber 2020. Hos­pi­tals and dis­trib­u­tors should stop the use of the drug and re­turn it to its place of pur­chase.

Any­one who be­lieves they are ex­pe­ri­enc­ing side ef­fects should con­tact their lo­cal doc­tor, as well as the FDA through its re­port­ing fea­ture on its web­site.

ICU Med­ical ac­quired the Hos­pi­ra In­fu­sion Sys­tems from Piz­er in Feb. 2017. The com­pa­ny man­u­fac­tures IV com­pound­ing sys­tems, as well as so­lu­tions, smart pumps and nee­dle-free con­nec­tors.

In May, one lot of Hos­pi­ra’s li­do­caine hy­drochlo­ride in­jec­tion was re­called af­ter its la­bel was switched with a lot of bupi­va­caine hy­drochlo­ride in­jec­tion. That is­sue was iden­ti­fied af­ter the FDA in­ves­ti­gat­ed a cus­tomer re­port, and marks the com­pa­ny’s sec­ond re­call in just four months.

Amgen is the latest pharma company to appear on the radar of Senate Finance Committee Chair Ron Wyden (D-OR), who is investigating the way pharma companies are using subsidiaries in low- or zero-tax countries to lower their tax bills.

Like its peers Merck, AbbVie and Bristol Myers Squibb, Wyden notes how Amgen uses its Puerto Rico operations to consistently pay tax rates that are substantially lower than the U.S. corporate tax rate of 21%, with an effective tax rate of 10.7% in 2020 and 12.1% in 2021.

As Ireland continues to see more investments and building projects from pharma companies, another contender is looking to place more investment in the Emerald Isle.

According to a report from The Irish Times on Friday, Abbott Laboratories is investing €440 million, or about $451 million, to build a new manufacturing plant in Kilkenny, located in the country’s southeast, to make more of its glucose monitors.

After controversially spinning out its talc liabilities and filing for bankruptcy in an attempt to settle 38,000 lawsuits, Johnson & Johnson is now changing up the formula for its baby powder products.

J&J is beginning the transition to an all cornstarch-based baby powder portfolio, the pharma giant announced on Thursday — just months after a federal judge ruled in favor of its “Texas two-step” bankruptcy to settle allegations that its talc products contained asbestos and caused cancer. An appeals court has since agreed to revisit that case.